Is the business good?
How good a business is RXRX?
Recursion Pharmaceuticals, Inc. keeps −881% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−881%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- +31%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 653%
R&D as % of revenue
- Gross margin
- 7.2%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −2136% |
| FY2021 | −1796% |
| FY2022 | −617% |
| FY2023 | −785% |
| FY2024 | −814% |
| FY2025 | −868% |
Details›
- Gross margin12 months to Q1 2026
- 7.2%
- Operating margin12 months to Q1 2026
- −881%
- Net margin12 months to Q1 2026
- −843%
- Free cash flow margin
- −491%
- R&D as % of revenue
- 653%
- Revenue, trailing twelve months
- $66M
- Free cash flow, trailing twelve months
- −$326M
- Net income, trailing twelve months
- −$560M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.